KalVista Pharmaceuticals Reports Phase 3 Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema February 23, 2024
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 6, 2023
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology November 2, 2023
